Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immatics N.V. - Ordinary Shares (NQ:IMTX)

5.515 -0.075 (-1.34%)
Streaming Delayed Price Updated: 11:25 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immatics N.V. - Ordinary Shares

< Previous 1 2 3 Next >
Ford Stock Slumps 7% on Analyst Downgrade
Ford (F) stock is losing traction on Monday after UBS analyst Patrick Hummel hit the automobile company's shares with a downgrade. 
Via InvestorPlace
Why Is Immatics (IMTX) Stock Up 7% Today?
Immatics (IMTX) stock is climbing higher on Monday after the biopharmaceutical company revealed an underwritten public offering. 
Via InvestorPlace
Immatics Immunotherapy Candidate Shows Confirmed Responses In Different Solid Cancers
 
Via Benzinga
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
From https://immatics.com/
Via GlobeNewswire
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. 
Via Benzinga
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65. 
Via Benzinga
Livent, Amgen And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing. 
Via Benzinga
Immatics: Q2 Earnings Insights
  Immatics (NASDAQ:IMTX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Immatics: Q2 Earnings Insights
Shares of Immatics (NASDAQ:IMTX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 21.62% year over year to ($0.45), which... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
UnitedHealth, Shockwave Lead 5 Healthy Stocks Breaking Out Or Setting Up
Shockwave and UnitedHealth lead 5 stocks that are setting up or breaking out. 
Via Investor's Business Daily
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
From Bristol Myers Squibb
Via Business Wire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Immatics Initiates Phase 1 Clinical Trial of IMA401 in Advanced Solid Tumors
Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1 clinical trial of its drug candidate IMA401 for patients with recurrent and/or refractory solid tumors. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 88 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Credit Suisse Group (NYSE:CS) was the largest, in terms of market cap... 
Via Benzinga
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
From Bristol Myers Squibb
Via Business Wire
Immatics Unveils Early-Stage Data Of TCR-Engineered Cell Therapy In Solid Tumors
Immatics N.V. (NASDAQ: IMTX) announced an interim clinical data update from its TCR-engineered cell therapy (TCR-T) approach ACTengine IMA203 targeting PRAME.... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers SCWorx (NASDAQ:WORX) shares rose... 
Via Benzinga
BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions
Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ: IMTX) to characterize T cell receptors (TCRs). T cell receptors and... 
Via Benzinga
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Obalon Therapeutics (NASDAQ:OBLN)... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.